Anavex Life Sciences Corp (AVXL)

[Joseph_K]

Answering my own question (or, more accurately, having ChatGPT help me answer it),

The numbers **-3.314** and **-0.251** are the **lower and upper bounds of the 95% confidence interval (CI)**, respectively, for the difference in LSM change from baseline to End-of-Trial between the drugged and placebo groups. The 95% CI is a range of values that is likely to contain the true value of the difference in LSM change from baseline to End-of-Trial between the drugged and placebo groups with a probability of 95%. In other words, if we were to repeat the clinical trial many times, we would expect that 95% of the time, the true value of the difference in LSM change from baseline to End-of-Trial between the drugged and placebo groups would fall within this range.

I conclude that the press release lacks sufficient information for anyone to determine the percentage by which blarcamesine slowed decline of the patients with respect to the conditions measured by ADAS-Cog13 and CDR-SB.